---
title: "Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA"
type: "Media Coverage"
date: "2026-11-16"
updated: "2026-11-16"
description: "Breakit reports on Sigrid’s SEK 45 million funding round and the company’s plans to grow in the US market."
url: "https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa"
canonical: "https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa"
markdown_url: "https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa.md"
site: "SiPore"
publisher: "SiPore Technologies (Sigrid Therapeutics AB)"
contact: "contact@sipore.com"
language: "en"
topics:
  - "Funding"
  - "US expansion"
  - "Growth strategy"
outlet: "Breakit"
original_url: "https://www.breakit.se/artikel/45100/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa"
---

# Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA

*Media Coverage · Nov 16, 2026 · Breakit*

> Breakit reports on Sigrid’s SEK 45 million funding round and the company’s plans to grow in the US market.

## Coverage

- **Outlet:** Breakit
- **Original article:** [Breakit](https://www.breakit.se/artikel/45100/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa)

Swedish tech outlet Breakit covered Sigrid’s SEK 45 million funding round, positioning the company as a challenger in the GLP-1 era and outlining its plans for expansion in the United States. The coverage points to strong investor confidence in the market opportunity for SiPore®.

## Related articles

- [Danska börsjättens framgångar ger fart till svensk uppstickare](https://sipore.com/insights/danska-borsjattens-framgangar-ger-fart-till-svensk-uppstickare.md) — Media Coverage, 2026-11-16
- [Sigrid Therapeutics utser Claus Kjærsgaard till ny VD](https://sipore.com/insights/sigrid-therapeutics-utser-claus-kjaersgaard-till-ny-vd.md) — Media Coverage, 2026-11-16

## How to cite

SiPore Technologies (Sigrid Therapeutics AB). “Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA”. SiPore, 2026-11-16. https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa (accessed <date>).

Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page.

## Company & contact

- **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M))
- **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden))
- **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com)
- **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com)
- **Origin:** Founded in Stockholm, Sweden
- **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.”
- **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion.

**Our sites** — all sites owned and operated by Sigrid Therapeutics AB:

- [SiPore.com](https://www.sipore.com/): Technology, science & partnerships
- [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources
- [SigridLife.com](https://sigridlife.com/): SIGRID consumer products
- [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden

---
[View on site](https://sipore.com/insights/ozempic-utmanaren-sigrid-therapeutics-backas-med-45-miljoner-ska-vaxa-i-usa) · [All insights](https://sipore.com/insights.md) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)
